| 1.39 0.01 (0.72%) | 09-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.01 | 1-year : | 2.31 |
| Resists | First : | 1.72 | Second : | 1.98 |
| Pivot price | 1.71 |
|||
| Supports | First : | 1.32 | Second : | 1.09 |
| MAs | MA(5) : | 1.57 |
MA(20) : | 1.74 |
| MA(100) : | 1.86 |
MA(250) : | 2.4 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.5  |
D(3) : | 10.8 |
| RSI | RSI(14): 27.8 |
|||
| 52-week | High : | 5.5 | Low : | 1.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ANVS ] has closed below the lower bollinger band by 9.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ANVS ] is to continue within current trading range. Bollinger Bands are 19.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.44 - 1.45 | 1.45 - 1.45 |
| Low: | 1.36 - 1.37 | 1.37 - 1.37 |
| Close: | 1.37 - 1.39 | 1.39 - 1.4 |
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Sat, 05 Sep 2026
Annovis Bio stock reacts to webinar plan and steep discount to analyst targets - AD HOC NEWS
Wed, 02 Sep 2026
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA - es.tradingview.com
Wed, 02 Sep 2026
ANVS: Top-line phase III Alzheimer's data expected in March, with NDA filing and funding plans in place - TradingView
Tue, 25 Aug 2026
Annovis says Alzheimer’s trial is fully enrolled, with data expected in 2027 - Stock Titan
Wed, 01 Jul 2026
Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Ahead of Phase 3 Milestones - citybiz
Wed, 17 Jun 2026
Annovis Bio shareholders approve all proposals at annual meeting - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 6.7 (%) |
| Held by Institutions | 27.9 (%) |
| Shares Short | 5,190 (K) |
| Shares Short P.Month | 4,860 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -142.4 % |
| Return on Equity (ttm) | -703.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.8 |
| PEG Ratio | 0 |
| Price to Book value | -13.85 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|